Results 91 to 100 of about 101,444 (326)

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

Dyslipidemia

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2011
Maëlle, Le Bras, Bertrand, Cariou
  +7 more sources

Palmitic acid alters enhancers/super-enhancers near inflammatory and efferocytosis-associated genes in human monocytes

Journal of Lipid Research
Free fatty acids like palmitic acid (PA) are elevated in obesity and diabetes and dysregulate monocyte and macrophage functions, contributing to enhanced inflammation in these cardiometabolic diseases.
Vinay Singh Tanwar, Marpadga A Reddy, Suchismita Dey, Vajir Malek, Linda Lanting, Zhuo Chen, Rituparna Ganguly, Rama Natarajan   +7 more
doaj   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Polygenic determinants in extremes of high-density lipoprotein cholesterol

Journal of Lipid Research, 2017
HDL cholesterol (HDL-C) remains a superior biochemical predictor of CVD risk, but its genetic basis is incompletely defined. In patients with extreme HDL-C concentrations, we concurrently evaluated the contributions of multiple large- and small-effect ...
Jacqueline S. Dron, Jian Wang, Cécile Low-Kam, Sumeet A. Khetarpal, John F. Robinson, Adam D. McIntyre, Matthew R. Ban, Henian Cao, David Rhainds, Marie-Pierre Dubé, Daniel J. Rader, Guillaume Lettre, Jean-Claude Tardif, Robert A. Hegele   +13 more
doaj   +1 more source

Syzygium polyanthum Extract as a therapy for dyslipidemia

, 2021
Satya Agusmansyah
openalex   +1 more source

Associations between Body Mass Index (BMI) and Dyslipidemia: Results from the PERSIAN Guilan cohort study (PSCS) [PDF]

, 2023
Jahangir Shahraz, Farahnaz Joukar, Sara Yeganeh, Fateme Sheida, Saman Maroufizadeh, Masood Baghaei, Mohammadreza Naghipour, Fariborz Mansour‐Ghanaei   +7 more
openalex   +1 more source

Temporal glomerular gene expression dynamics during disease progression in a mouse model of hypertension‐accelerated diabetic kidney disease

Animal Models and Experimental Medicine, EarlyView.
The current study characterized temporal changes in glomerular gene expression, pathology, and biomarkers in a mouse model of hypertension‐accelerated diabetic kidney disease (DKD). Progressive albuminuria and glomerulosclerosis were paralleled by dynamic transcriptomic changes associated withmetabolic dysfunction, extracellular matrix remodeling, and ...
Adam B. Marstrand‐Jørgensen, Frederikke Emilie Sembach, Maria Ougaard, Ditte Hansen, Mette Viberg Østergaard, Henrik H. Hansen, Louise S. Dalbøge, Ole Jørgen Kaasbøll, Michael Christensen   +8 more
wiley   +1 more source

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

Journal of Lipid Research, 2017
Familial dysbetalipoproteinemia (FD) is a genetic disorder associated with impaired postprandial lipid clearance. The effect of adding bezafibrate to standard lipid-lowering therapy on postprandial and fasting lipid levels in patients with FD is unknown.
Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, Frank L.J. Visseren   +4 more
doaj   +1 more source

ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk

Digital Doctor, 2020

semanticscholar   +1 more source